In Vitro Activity of Cefotetan against ESBL-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Isolates from the MERINO Trial-Reference-Cited by-同舟云学术

In Vitro Activity of Cefotetan against ESBL-Producing Escherichia coli and Klebsiella pneumoniae Bloodstream Isolates from the MERINO Trial

Published:2021-09-03 Issue:1 Volume:9 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Stewart Adam G.¹²³^ORCID,Cottrell Kyra²,Henderson Andrew²⁴,Vemuri Kanthi¹²³,Bauer Michelle J.²,Paterson David L.¹²^ORCID,Harris Patrick N. A.²³^ORCID

Affiliation:

1. Department of Infectious Diseases, Royal Brisbane and Women’s Hospital, Brisbane, Australia

2. Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Royal Brisbane and Women’s Hospital Campus, Brisbane, Australia

3. Central Microbiology, Pathology Queensland, Royal Brisbane and Women’s Hospital, Brisbane, Australia

4. Infection Management Services, Princess Alexandra Hospital, Brisbane, QLD, Australia

Abstract

Carbapenem antibiotics remain the treatment of choice for severe infection due to ESBL- and AmpC-producing Enterobacterales . The use of carbapenems is a major driver of the emergence of carbapenem-resistant Gram-negative bacilli, which are often resistant to most available antimicrobials.

Funder

Novartis AG | Sandoz

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/Spectrum.00226-21

Reference17 articles.

1. Past and Present Perspectives on β-Lactamases

2. Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016–2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam

3. Antibiotic resistance threats in the United States, 2019